Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
B7-33 — a single-chain relaxin (H2) peptide analog acting at the RXFP1 receptor, studied in anti-fibrosis and tissue-remodeling models. Lyophilized, HPLC ≥98%.
Size: 10 mg
No published analyses yet.
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (week 1) | 100 mcg, once daily | Starting dose |
| Maintenance | 100–250 mcg, once daily | Increase if needed |
| Maximum in schedule | 250 mcg, once daily | Maximum in this schedule |
| Cycle length | 4–8 weeks | , |
Share your experience
No reviews yet. Tell others what you think of this product.
B7-33 is a synthetic single-chain peptide derived from the B-chain of human relaxin-2 and the first reported functionally selective (biased) agonist of the RXFP1 receptor. Unlike two-chain native relaxin, it reproduces the core anti-fibrotic signalling (via the pERK1/2 axis) within a single short chain that is far simpler to synthesise.
In preclinical research (the Hossain and Bathgate groups at the Florey Institute), B7-33 showed anti-fibrotic and vasoprotective activity in cell and rodent models of the heart, lung and kidney, reduced infarct size in mice, and — unlike full-length relaxin — did not promote prostate tumour growth.
This is a rare, frontier research compound that Longeva keeps in stock when others will not source it.
